Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...

Sarepta stock surged after the pharma company said it would lay off a third of its workforce and add a black-box warning to ...

Sarepta Therapeutics shares surged 34% in after-hours trading on Wednesday after the company said it would slash 500 jobs, or ...

Sarepta Therapeutics Inc. shares soared after the company said it was cutting more than a third of its workforce and that its ...

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

Sarepta stock catapulted Wednesday after the company announced a restructuring that includes 500 layoffs in the wake of two patient deaths.

Sarepta Therapeutics said on Wednesday it would lay off 36% of its workforce, or about 500 employees, after the recent deaths of two patients who had received its gene therapy Elevidys.

The company is also pausing research for several treatments it has been developing for another form of muscular dystrophy.

The drastic cost-cutting move followa the deaths of two teenagers that forced the company to restrict usage of its gene ...

The company aims to focus on high-impact programmes to meet its 2027 financial obligations and support long-term viability.

Sarepta Therapeutics said it will eliminate 36% of its workforce—approximately 500 jobs—in a restructuring that follows the ...

Sarepta Therapeutics announced it has laid off more than one-third of its workforce, a drastic cost-cutting move following ...